RARA CRAFT DATABASE for FDA Medical Devices
510(k)K222225

FDA DEVICE FACTS

Nitrile Powder Free Examination Glove Tested for Use with Chemotherapy Drugs (Blue)

Hartalega NGC Sdn. Bhd.

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATENovember 11, 2022PRODUCT CODELZA

Indications for use

Nitrile Powder Free Examination Glove Tested for Use with Chemotherapy Drugs (Blue) is a non-sterile disposable device intended for medical purpose that is worn on the examiner's hand to prevent contamination between patient and examiner. It is also tested to be used against Chemotherapy Drugs. These gloves were tested for use with chemotherapy drugs as per ASTM D6978-05 (Reapproved 2019) Standard Practice for Assessment of Medical Gloves to Permeation by Chemotherapy Drugs. Chemotherapy Drug and Concentration Carmustine (3.3 mg/ml) Cisplatin (1.0 mg/ml) Cyclophosphamide (20.0 mg/ml) Dacarbazine (10.0 mg/ml) Doxorubicin Hydrochloride (2.0 mg/ml) Etoposide (20.0 mg/ml) Fluorouracil (50.0 mg/ml) Methotrexate (25.0 mg/ml) Mitomycin C (0.5 mg/ml) Paclitaxel (6.0 mg/ml) Thiotepa (10.0 mg/ml) Vincristine Sulfate (1.0 mg/ml) Bleomycin Sulfate, 15.0 mg/ml Bortezomib, 1.0 mg/ml Busulfan, 6.0 mg/ml Carboplatin, 10.0 mg/ml Chloroquine, 50.0 mg/ml Cyclosporin A, 100.0 mg/ml Cytarabine, 100.0 mg/ml Daunorubicin, 5.0 mg/ml Docetaxel, 10.0 mg/ml Epirubicin, 2.0 mg/ml Fludarabine, 25.0 mg/ml Gemcitabine, 38.0 mg/ml Idarubicin, 1.0 mg/ml lfosfamide, 50.0 mg/ml Irinotecan, 20.0 mg/ml Mechlorethamine HCI, 1.0 mg/ml Melphalan, 5.0 mg/ml Mitoxantrone, 2.0 mg/ml Oxaliplatin, 2.0 mg/ml Paraplatin, 10.0 mg/ml Retrovir, 10.0 mg/ml Rituximab, 10.0 mg/ml Topotecan, 1.0 mg/ml Minimum Breakthrough Detection Time in Minutes 10.2 >240 >240 >240 >240 >240 >240 >240 >240 >240 30.2 >240 >240 >240 >240 >240 >240 >240 >240 >240 >240 >240 >240 >240 >240 >240 >240 >240 >240 >240 >240 >240 >240 >240 >240 PSC Publi,hlng S=ices (301) 443-6740 BF Trisenox, 1.0 mg/ml >240 Caution: Testing showed an average breakthrough time of 10.2 minutes with Carmustine and 30.2 minutes with Thiotepa. Warning: Do not use with Carmustine and Thiotepa

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 22, 2026